论文部分内容阅读
目的观察通心络胶囊治疗急性冠脉综合征患者血清可溶性CD40L(sCD40L)的变化,了解其对斑块稳定和免疫炎症抑制的影响。方法50例急性冠脉综合征患者,随机分为通心络治疗组(n=33)和他汀类治疗组(n=17),测定治疗前后血清sCD40L水平的变化。结果两组患者血清治疗前后sCD40L水平明显下降,通心络组下降34.6%,他汀类组下降33.4%,与治疗前比较均有统计学差异(P<0.01);而两组用药前比较和用药后比较均无统计学差异(P>0.05)。结论急性冠脉综合征患者早期予以通心络胶囊治疗一疗程,可明显降低sCD40L的水平,有利于动脉粥样硬化斑块的稳定。
Objective To observe the changes of serum soluble CD40L (sCD40L) in patients with acute coronary syndromes treated with Tongxinluo Capsule, and to understand its effect on plaque stability and immune inflammation suppression. Methods Fifty patients with acute coronary syndrome were randomly divided into Tongxinluo treatment group (n = 33) and statin treatment group (n = 17). Serum sCD40L levels were measured before and after treatment. Results Serum levels of sCD40L decreased significantly in both groups before and after treatment, decreased by 34.6% in Tongxinluo group and 33.4% in statin group, compared with those before treatment (P <0.01) After the comparison there was no statistical difference (P> 0.05). Conclusion Patients with acute coronary syndrome treated with Tongxinluo capsule for a course of treatment can significantly reduce the level of sCD40L and promote the stability of atherosclerotic plaque.